[Plasma fibronectin in acute leukemia. Effects of the cytostatic therapy on plasma fibronectin level].
Twice a week plasma (Pl.)-fibronectin was determined quantitatively in the course of disease with immunoelectrophoresis according to Laurell in 12 patients suffered from acute non-lymphoblastic leukemia (ANLL) and in 12 patients affected with acute lymphoblastic leukemia (ALL). At diagnosis Pl.-fibronectin concentration was found to be significantly lowered only in those patients affected with ANLL. During the induction therapy Pl.-Fibronectin could be observed to decline significantly in all patients: in acute non-lymphoblastic leukemia from mean 270 micrograms/ml, s 93 micrograms/ml, to mean 185 micrograms/ml, s 89 micrograms/ml (p less than 0.01), and in acute lymphoblastic leukemia from mean 290 micrograms/ml, s 98 micrograms/ml, to mean 180 micrograms/ml, s 94 micrograms/ml (p less than 0.01). After administering L-asparaginase there is a strong decline of Pl.-fibronectin. Pl.-fibronectin concentration could be observed to be significantly lower in patients without remission in comparison to those with remission. A correlation between Pl.-fibronectin concentration and tumour mass could not be identified.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001215:Asparaginase / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D005353:Fibronectins / Q000097:blood*; D006801:Humans; D007938:Leukemia / Q000097:blood* / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000097:blood / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D000970:Antineoplastic Agents; D005353:Fibronectins; D001215:Asparaginase
Plasma-Fibronectin bei akuter Leukämie. Der Einfluss der zytostatischen Therapie auf den Plasma-Fibronectinspiegel.